Influence of a Lipoprotein(a)-Lowering Therapy on Insulin Sensitivity

• Conditions: E78.5; Hyperlipidaemia, unspecified

• Registration Number: DRKS00031748
• Lead Sponsor: Charité Universitätsmedizin Berlin

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-05-02
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 13

Inclusion Criteria

dyslipidemia
- initiation of PCSK-9-antibody therapy planned
- age =18 years
- written informed consent
- sex: male or female (post-menopausal)

Exclusion Criteria

- diabetes mellitus or intake of antidiabetic drugs
- pregnancy
- history of thrombosis or high risk for thrombosis [cancer disease, recent surgeries (within 6 weeks), genetic thrombophilia (APC resistance, Protein S deficiency, antithrombin deficiency, Prothrombin G20210A, MTHFR gene mutation)]
- pacemaker or defibrillator
- intake of unknown (study) drugs

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change of insulin resistance in the muscle

Secondary Outcome Measures

Name	Time	Method
- Change of insulin resistance in the liver<br>- Change of insulin resistance in adipose tissue